Situation
A chromatography data system (CDS) processing method is revised to address peak integration for a new formulation matrix.
Intended Use
Acquire chromatographic data, apply the approved processing method, permit controlled reintegration, calculate results, and retain review evidence.
Decision Summary
| Decision element | Case record |
|---|---|
| GxP assessment | Processing parameters, manual integration, calculation, audit history, review, and reported result support laboratory decisions used for release. |
| Potential impact | An incorrect analytical result can support an incorrect material or product decision. |
| Known issue | A fictional low-area shoulder peak is omitted under one processing threshold. |
| Validation conclusion | The processing method is not approved until threshold rationale, expected result, reviewer instruction, and regression evidence are corrected. |
GxP Assessment
Processing parameters, manual integration, calculation, audit history, review, and reported result support laboratory decisions used for release.
Affected GxP Functions
- Processing-method version
- Peak detection and integration
- Manual reintegration authorization
- Result calculation and report
- Audit-trail review
Failure Scenarios
- Wrong method version is applied
- A reportable peak is excluded
- Unauthorized reintegration changes the result
- Rounding changes specification status
- Audit review misses the change
Potential Impact
An incorrect analytical result can support an incorrect material or product decision.
Existing Controls
- Controlled method approval
- Role restrictions
- Second-person data review
- Audit-trail review procedure
- Instrument suitability
Existing Evidence
- Qualified CDS and instrument
- Prior method validation data
- Supplier calculation tests
- Approved analytical procedure
Evidence Gaps
- New matrix behavior
- Method-version transition
- Manual integration boundaries
- Report rounding
Testing Approach
- Use representative chromatograms with independently established expected results
- Challenge version selection and unauthorized integration
- Test calculation and rounding boundaries
- Verify raw data, method, audit history, report, and review traceability
Deviations or Known Issues
A fictional low-area shoulder peak is omitted under one processing threshold.
Validation Conclusion
The processing method is not approved until threshold rationale, expected result, reviewer instruction, and regression evidence are corrected.
Reassessment Criteria
- Processing-method parameter change
- CDS or integration-engine update
- New matrix or detector
- Review procedure change
- Out-of-specification investigation
Limitations and unresolved questions
A limited set of standard samples does not demonstrate suitability for all matrices. The missed shoulder peak requires method-specific correction and reviewer evidence.
Relevant regulations and guidance
These sources apply within their stated scope. The suggested worksheet fields, test designs and fictional decisions are practitioner recommendations, unless a source requirement is expressly identified. Completing a template does not establish compliance.
Computer Software Assurance for Production and Quality Management System Software ↗
Regulatory guidance / GMP guideline · United States · February 2026
Scope: Medical-device manufacturers assuring software used in production or their quality management system.
Relevance: For medical-device production or QMS software, supports selecting assurance activities from intended use, risk and available evidence. It is nonbinding guidance and does not determine other sectors’ obligations.
Status: Final / published · Checked 2026-09-21
Publication identity, scope and status checked against the linked official source. This is not an independent audit of every retained guide statement.
Read source details and applicability →EudraLex Volume 4, Annex 11 — Computerised Systems ↗
Regulatory guidance / GMP guideline · European Union · January 2011 revision
Scope: Computerised systems supporting activities in the applicable EU pharmaceutical GMP context.
Relevance: For computerised systems used in EU GMP activities, informs lifecycle, supplier and record controls. Confirm applicability to the actual activity; the example does not establish it.
Status: Final / published · Checked 2026-09-21
The Commission index confirms the January 2011 operative revision. The linked PDF could not be retrieved in this check; retained detailed section mappings need review against an authorized copy.
Read source details and applicability →Was this useful? Leave feedback
Was this resource useful?
Tell us what helped and what could be clearer. Usefulness feedback does not establish technical validity or regulatory compliance.
Loading contribution options…
Questions and moderated discussion
Questions and discussion
What additional information would you need before making this decision?
Loading contribution options…
Suggest a correction
Sent privately to the editorial moderation queue. Your account email and correction are not published as a comment. Do not include confidential or personal information.
Resource: Chromatography Data System Processing Method
Loading sign-in status…